Selected data models

You must log in to select data models for download or further analysis.

44 Search results.
Relevance Rating New first Old first

CLL Eligibility BO17072 NCT00090051 - Eligibility Chronic Lymphocytic Leukemia NCT00090051

- 11/18/21 - 1 form, 3 itemgroups, 37 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria, Eligibility summary
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

CLL Completion BO17072 NCT00090051 - Treatment phase completion Chronic Lymphocytic Leukemia BO17072 NCT00090051

- 9/27/21 - 1 form, 3 itemgroups, 14 items, 1 language
Itemgroups: Death of Patient, Treatment phase completion, Additional observations
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051

CLL History BO17072 NCT00090051 - History of Chronic lymphocytic leukemia NCT0090051

- 9/27/21 - 1 form, 5 itemgroups, 13 items, 1 language
Itemgroups: Vital signs and physical measurements, Sitting measurements, "B" symptoms, General physical examination, ECG
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

CLL Cycle 1 FCR vs FC BO17072 NCT00090051 - Chemotherapy Cycle 1 of Chronic Lymphocytic Leukemia NCT00090051 BO17072

- 9/27/21 - 1 form, 16 itemgroups, 80 items, 1 language
Itemgroups: Randomization, Pharmacokinetic assessments, Vital signs and physical measurements, Sitting measurements after al least 5 minutes rest, "B" symptoms, General physical examination, ECG, Laboratory analysis, Hematology, Blood chemistry, Electrocytes, Administration of Rituximab, Administration of Fludarabine, Fludarabine Medication, Administration of Cyclophosphamide, Cyclophosphamide Medication
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

Eligibility Leukemia NCT00004857

- 9/20/21 - 1 form, 1 itemgroup, 20 items, 1 language
Itemgroup: Criteria
Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00004857

Eligibility Leukemia, B-Cell, Chronic NCT00344825

- 9/20/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00344825

Eligibility Acute Myeloid Leukemia NCT02034227

- 9/20/21 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia; ODM derived from: http://clinicaltrials.gov/show/NCT02034227

CLL Demographics and Medical History BO17072 NCT00090051 - Demographics and Medical History Chronic Lymphocytic Leukemia NCT00090051

- 3/15/21 - 1 form, 8 itemgroups, 28 items, 1 language
Itemgroups: Demographics, Serum pregnancy test, History of diseases, History of treatments, Previous treatments chemotherapy, Previous treatments radiotherapy, Surgery, Other treatment
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051 Roche BO17072 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Eligibility B-cell Chronic Lymphocytic Leukemia NCT01217749

- 8/15/19 - 1 form, 2 itemgroups, 32 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL; ODM derived from: https://clinicaltrials.gov/show/NCT01217749

Eligibility Lymphocytic Leukemia, Chronic NCT01283386

- 1/17/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status; ODM derived from: https://clinicaltrials.gov/show/NCT01283386

Eligibility Richter's Transformation NCT00472849

- 8/30/17 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias; ODM derived from: https://clinicaltrials.gov/show/NCT00472849

Eligibility Leukemia, Lymphocytic, Chronic NCT00464633

- 8/4/17 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00464633

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial